Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by HC Wainwright

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $92.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 123.79% from the company’s previous close. […]

Related Keywords

Pascal Deschatelets ,Robertw Baird ,Timothy Eugene Sullivan ,Polar Capital Holdings Plc ,Apellis Pharmaceuticals Inc ,Apellis Pharmaceuticals Stock Performance ,Norges Bank ,Vanguard Group Inc ,Jefferies Financial Group ,News Ratings For Apellis Pharmaceuticals Daily ,Apellis Pharmaceuticals ,Jpmorgan Chase Co ,Securities Exchange Commission ,Wells Fargo Company ,Analyst Recommendations For Apellis Pharmaceuticals ,Pricet Rowe Associates Inc ,Get Free Report ,Financial Group ,Exchange Commission ,Eugene Sullivan ,Capital Holdings Plc ,Apellis Pharmaceuticals Daily ,